Literature DB >> 18028910

Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies.

Charbel E-H Moussa1, Milan Rusnak, Ayichew Hailu, Anita Sidhu, Stanley T Fricke.   

Abstract

Animal models treated with agricultural chemicals, such as rotenone, reproduce several degenerative features of human central nervous system (CNS) diseases. Glutamate is the most abundant excitatory amino acid transmitter in the mammalian central nervous system and its transmission is implicated in a variety of brain functions including mental behavior and memory. Dysfunction of glutamate neurotransmission in the CNS has been associated with a number of human neurodegenerative diseases, either as a primary or as a secondary factor in the excitotoxic events leading to neuronal death. Since many human CNS disorders do not arise spontaneously in animals, characteristic functional changes have to be mimicked by toxic agents. Candidate environmental toxins bearing any direct or indirect effects on the pathogenesis of human disease are particularly useful. The present longitudinal Magnetic Resonance Imaging (MRI) studies show, for the first time, significant variations in the properties of brain ventricles in a rotenone-treated (2 mg/kg) mouse model over a period of 4 weeks following 3 days of rotenone treatment. Histopathological analysis reveals death of stria terminalis neurons following this short period of rotenone treatment. Furthermore, in vivo voxel localized (1)H MR spectroscopy also shows for the first time significant bio-energetic and metabolic changes as well as temporal alterations in the levels of glutamate in the degenerating striatal region. These studies provide novel insights on the effects of environmental toxins on glutamate and other amino acid neurotransmitters in human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028910      PMCID: PMC3466058          DOI: 10.1016/j.expneurol.2007.09.023

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  63 in total

1.  [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study.

Authors:  D S Higgins; J T Greenamyre
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

2.  Expression of the glutamate transporter GLT1 in neural cells of the rat central nervous system: non-radioactive in situ hybridization and comparative immunocytochemistry.

Authors:  A Schmitt; E Asan; B Püschel; T Jöns; P Kugler
Journal:  Neuroscience       Date:  1996-04       Impact factor: 3.590

3.  ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

Authors:  L I Bruijn; M W Becher; M K Lee; K L Anderson; N A Jenkins; N G Copeland; S S Sisodia; J D Rothstein; D R Borchelt; D L Price; D W Cleveland
Journal:  Neuron       Date:  1997-02       Impact factor: 17.173

4.  Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study.

Authors:  T Arzberger; K Krampfl; S Leimgruber; A Weindl
Journal:  J Neuropathol Exp Neurol       Date:  1997-04       Impact factor: 3.685

5.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

6.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

7.  Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations.

Authors:  K P Lehre; L M Levy; O P Ottersen; J Storm-Mathisen; N C Danbolt
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

8.  Inhibitors of glutamate transport modulate distinct patterns in brain metabolism.

Authors:  Charbel E-H Moussa; Caroline Rae; William A Bubb; Julian L Griffin; Natasha A Deters; Vladimir J Balcar
Journal:  J Neurosci Res       Date:  2007-02-01       Impact factor: 4.164

9.  Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease.

Authors:  E Masliah; M Alford; R DeTeresa; M Mallory; L Hansen
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

10.  Parkinson's disease: a test of the multifactorial etiologic hypothesis.

Authors:  K M Semchuk; E J Love; R G Lee
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

View more
  3 in total

1.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

2.  Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.

Authors:  L V Darbinyan; L E Hambardzumyan; K V Simonyan; V A Chavushyan; L P Manukyan; S A Badalyan; N Khalaji; V H Sarkisian
Journal:  Metab Brain Dis       Date:  2017-07-10       Impact factor: 3.584

3.  Mitochondrial dysfunction in aging rat brain regions upon chlorpyrifos toxicity and cold stress: an interactive study.

Authors:  P Mahaboob Basha; Annappa Poojary
Journal:  Cell Mol Neurobiol       Date:  2014-04-18       Impact factor: 5.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.